Showing results (51-60 of 59) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 59 results.
Cancer|August 17, 2025
Detectable prostate-specific antigen after radiotherapy for clinically localized prostate cancerUgo Giovanni Falagario, Francesco Pellegrino, Ahmad Abbadi, et al.
European Urology Oncology|June 22, 2025
Epidemiology of High-risk Biochemical Recurrence After Primary Prostate Cancer TreatmentUgo Giovanni Falagario, Francesco Pellegrino, Lars Björnebo, et al.
NEJM Evidence|February 6, 2024
Enzalutamide and Quality of Life in Biochemically Recurrent Prostate CancerStephen J Freedland, Martin Gleave, Ugo De Giorgi, et al.
World Journal of Urology|December 9, 2022
When to order genomic tests: development and external validation of a model to predict high-risk prostate cancer at the genotypic levelUgo Giovanni Falagario, Dimple Chakravarty, Alberto Martini, et al.
European Urology Oncology|September 25, 2020
Combined Use of Prostate-specific Antigen Density and Magnetic Resonance Imaging for Prostate Biopsy Decision Planning: A Retrospective Multi-institutional Study Using the Prostate Magnetic Resonance Imaging Outcome Database (PROMOD)Ugo Giovanni Falagario, Ivan Jambor, Anna Lantz, et al.
BJU International|February 5, 2025
Refining partial gland ablation for localised prostate cancer: the FALCON projectLara Rodriguez-Sanchez, Xavier Cathelineau, Theo M de Reijke, et al.
European Urology Open Science|July 11, 2022
The Mount Sinai Prebiopsy Risk Calculator for Predicting any Prostate Cancer and Clinically Significant Prostate Cancer: Development of a Risk Predictive Tool and Validation with Advanced Neural Networking, Prostate Magnetic Resonance Imaging Outcome Database, and European Randomized Study of Screening for Prostate Cancer Risk CalculatorSneha Parekh, Parita Ratnani, Ugo Falagario, et al.
European Urology|August 13, 2022
Predicting the Need for Biopsy to Detect Clinically Significant Prostate Cancer in Patients with a Magnetic Resonance Imaging-detected Prostate Imaging Reporting and Data System/Likert ≥3 Lesion: Development and Multinational External Validation of the Imperial Rapid Access to Prostate Imaging and Diagnosis Risk ScoreMax Peters, David Eldred-Evans, Piet Kurver, et al.
World Journal of Urology|October 3, 2023
Diagnosis of prostate cancer with magnetic resonance imaging in men treated with 5-alpha-reductase inhibitorsUgo G Falagario, Anna Lantz, Ivan Jambor, et al.
Pageof 6